Kindeva Careers
Inventive, curious, and committed to results? We’re hiring.
Explore Job OpportunitiesNews
Whether making headlines for our work—or creating info you need now—you can find it here.
Kindeva Drug Delivery to Acquire iPharma Labs Inc.
Virpax Pharmaceuticals Selects Kindeva Drug Delivery as Development Partner for Diclofenac pMDI Commercialization
Live-Attenuated VEEV Vaccine Delivered by iDNA Using Microneedles Is Immunogenic in Rabbits
Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva
Kindeva Drug Delivery to Manufacture New, Greener Inhalers at UK Manufacturing Site to Help Cut Carbon Emissions
Kindeva Welcomes Mike Ratigan to the Leadership Team
IPAC-RS Welcomes Kindeva’s Mike Needham to the Board
Nutriband Inc. and Kindeva Drug Delivery sign feasibility agreement to develop AVERSA™ Fentanyl, an abuse deterrent fentanyl patch
Steve Fuechtmann Joins Kindeva Drug Delivery as CFO
Kindeva Drug Delivery commits to sustainable inhaler production with significant new manufacturing investment
Drug Delivery Veteran, Raj Khankari, joins Kindeva Drug Delivery
Accelerating sustainable healthcare product development.
The Medical Alley Association Welcomes Kindeva Drug Delivery CEO Aaron Mann to Board of Directors
Kindeva Drug Delivery Announces Collaboration with Monash University to Study Sustainable Propellants
Kindeva Drug Delivery Announces Knowledge Transfer Partnership with Loughborough University to Study Sustainable Propellants
Kindeva Appoints Greg Sargen to Board of Directors
Kindeva Drug Delivery and Cambridge Healthcare Innovations Limited to Collaborate on Development of Novel Dry-Powder Inhaler Product
Kindeva seals deal to expand operations at Charnwood Campus
Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol
Kindeva Appoints Shawn Cavanagh to Board of Directors
Kindeva and BOL Pharma Sign Agreement for Development of Inhaled Cannabinoid Products
Kindeva Drug Delivery Celebrates Breaking Ground for New Headquarters
Q&A with Kindeva Drug Delivery: Putting patients at the centre of drug development
Planning for Brexit : A case study on the strategic role CDMOs can play for their customers
Kindeva experts speak with ODD about future innovation in sustainable inhalation drug delivery
Kindeva scientists talk to BBC Witness History about the world's first modern asthma inhaler
Kindeva experts talk to PMPS about the lasting impact COVID-19 will have on drug delivery
Show, don't tell: how CDMO quality systems affect your product
Biotech's mirrored universe: predictive engineering and digital twinning
Addressing the challenges of vaccines and intradermal delivery
Kindeva: A historic CDMO, reborn
Kindeva talks to the Star Tribune about its launch as an independent company
Kindeva Drug Delivery launches as an independent company
Events
Whether leading, attending, or hosting, we stay busy and in the loop.
˅
Soft Mist Inhaler: Ready for Your Molecules, Webinar
Soft Mist Inhaler: Ready for Your Molecules
April 6, 2022 at 9 a.m. CDT
This webinar will be an in-depth analysis of SMI technology to harness its potential: design, performance, use and benefits in the development of Inhaled dosage forms.
• How to formulate SMIs
• How to test SMIs
• How to launch SMIs
The webinar will take MRX004 SMI as an example and review what it offers: a simplified and de-risked device platform, versatile enough to be used with soluble and insoluble APIs. Kindeva and Merxin have worked together to generate performance data that will showcase SMI and MRX004 opportunities. Merxin makes the device, Kindeva develops the formulations and executes the performance testing.
Click here to register. This webinar is free to attend.
˅
Respiratory Drug Delivery 2022
Respiratory Drug Delivery 2022
Omni Orlando ChampionsGate, Florida
In Person May 1-5, 2022
Virtual April 25-June 30, 2022
Respiratory Drug Delivery and the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) will again collaborate to develop a jointly organized session on Thursday May 5 that will address Regulatory, Science and Technology Innovations Enabling Novel and Improved OINDP Design, Development and Manufacturing. The podium presentations will be supplemented with subsequent in-depth roundtables (delivered online after RDD 2022).
Click here to register.